DOP2007000021A - Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb - Google Patents

Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb

Info

Publication number
DOP2007000021A
DOP2007000021A DO2007000021A DO2007000021A DOP2007000021A DO P2007000021 A DOP2007000021 A DO P2007000021A DO 2007000021 A DO2007000021 A DO 2007000021A DO 2007000021 A DO2007000021 A DO 2007000021A DO P2007000021 A DOP2007000021 A DO P2007000021A
Authority
DO
Dominican Republic
Prior art keywords
weight loss
trkb agonist
managing
procedures
treating unwanted
Prior art date
Application number
DO2007000021A
Other languages
English (en)
Inventor
Arnon Rosenthal
John Chia-Yang Lin
Jennifer Renee Stratton
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of DOP2007000021A publication Critical patent/DOP2007000021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a procedimientos para tratar pérdida de peso corporal no deseada (tal como caquexia), trastornos alimentarios (tales como anorexia nerviosa), o emesis inducida por opioides mediante administración periférica de un agonista de trkB. La invención también se refiere a composiciones y kits que comprenden un agonista de trkB.
DO2007000021A 2006-02-02 2007-02-01 Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb DOP2007000021A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76541006P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
DOP2007000021A true DOP2007000021A (es) 2007-08-31

Family

ID=38093467

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2007000021A DOP2007000021A (es) 2006-02-02 2007-02-01 Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb

Country Status (17)

Country Link
US (2) US20070248611A1 (es)
EP (1) EP1988923A1 (es)
JP (1) JP2009528985A (es)
KR (1) KR20080091838A (es)
CN (1) CN101400367A (es)
AR (1) AR059304A1 (es)
AU (1) AU2007210862A1 (es)
BR (1) BRPI0707482A2 (es)
CA (1) CA2637826A1 (es)
DO (1) DOP2007000021A (es)
IL (1) IL193069A0 (es)
NL (1) NL2000464C2 (es)
PE (1) PE20071364A1 (es)
RU (1) RU2008131939A (es)
TW (1) TW200808352A (es)
UY (1) UY30128A1 (es)
WO (1) WO2007088476A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
WO2008058127A2 (en) * 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
JP2010513461A (ja) * 2006-12-20 2010-04-30 ライナット ニューロサイエンス コーポレイション 自己免疫障害を治療するためのＴｒｋＢアゴニスト
KR20100089851A (ko) * 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
GB2491106A (en) * 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
US11078287B2 (en) 2015-11-17 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
SG11202002665UA (en) * 2017-11-30 2020-04-29 Regeneron Pharma Anti-trkb monoclonal antibodies and methods of use

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5364768A (en) * 1987-07-07 1994-11-15 Farmitalia Carlo Erba S.R.L. Process for the preparation of penems
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
US6566091B1 (en) * 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US5702906A (en) * 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
CA2055812A1 (en) * 1990-11-20 1992-05-21 Carl N. Skold Method of stabilizing enzyme conjugates
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994005697A1 (en) * 1992-09-07 1994-03-17 The Agricultural And Food Research Council Growth hormone potentiating molecules
CA2144539A1 (en) * 1992-09-14 1994-03-31 Judith Siuciak Method of producing analgesia using neurotrophins
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
DK0695169T3 (da) * 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
JP2534968B2 (ja) * 1993-05-27 1996-09-18 チッソ株式会社 フラビン還元酵素遺伝子
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
WO1995031183A1 (en) * 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
DE59510779D1 (de) * 1994-06-24 2003-10-02 Dade Behring Marburg Gmbh Verfahren zur Stabilisierung von hydrolyseempfindlichen Molekülen
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
HU222666B1 (hu) 1996-11-15 2003-09-29 Genentech, Inc. Eljárás neuorotrofinok tisztítására
KR20000070357A (ko) * 1997-01-23 2000-11-25 다께우찌 마사야쓰 당뇨병 치료제
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
NZ502820A (en) * 1997-08-29 2002-10-25 Vertex Pharma Heteroaryl or aryl substituted carboxylic acid or carboxamide derivatives optionally substituted with a sulphonamido group
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
JP2003503476A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミド誘導体
WO2001002362A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Azo amino acid derivatives for the treatment of neurological diseases
AU5919900A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated Cyclized amino acid derivatives
AU5912900A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
EP1196400A1 (en) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Amino-alkyl derivatives
WO2001008685A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
CA2385929A1 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
WO2001060398A1 (fr) * 2000-02-18 2001-08-23 Sumitomo Pharmaceuticals Company, Limited Medicaments destines a ameliorer l'intolerance au glucose
EP1262189A1 (en) * 2000-03-06 2002-12-04 Sumitomo Pharmaceuticals Company, Limited Leptin-resistance ameliorating agents
NZ523105A (en) 2000-06-22 2004-07-30 Genentech Inc Agonist anti-trk-C monoclonal antibodies
US7060429B2 (en) * 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
KR20040007714A (ko) * 2001-06-14 2004-01-24 버텍스 파마슈티칼스 인코포레이티드 신경 손상 치료에 유용한 비환식 피페라진 및 피페리딘유도체
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Also Published As

Publication number Publication date
CA2637826A1 (en) 2007-08-09
EP1988923A1 (en) 2008-11-12
TW200808352A (en) 2008-02-16
JP2009528985A (ja) 2009-08-13
AR059304A1 (es) 2008-03-26
NL2000464A1 (nl) 2007-08-03
BRPI0707482A2 (pt) 2011-05-03
UY30128A1 (es) 2007-09-28
RU2008131939A (ru) 2010-02-10
PE20071364A1 (es) 2008-01-30
KR20080091838A (ko) 2008-10-14
CN101400367A (zh) 2009-04-01
US20090291897A1 (en) 2009-11-26
WO2007088476A1 (en) 2007-08-09
IL193069A0 (en) 2009-02-11
AU2007210862A1 (en) 2007-08-09
US20070248611A1 (en) 2007-10-25
NL2000464C2 (nl) 2007-09-11

Similar Documents

Publication Publication Date Title
DOP2007000021A (es) Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb
CR10444A (es) Anticuerpo humanizado de c-kit
MX2009006304A (es) Nuevos compuestos de oxadiazol.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
DOP2009000149A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
JO3313B1 (ar) التراكيب والطرق لزيادة نمو العضلة
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
NI201000138A (es) Compuestos
IN2012DN01241A (es)
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
HN2010001761A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
GT200700064A (es) Agonistas de ep2
UY32125A (es) Compuestos novedosos como ligandos de receptores de canabinoides
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
IL193479A0 (en) Modulators of muscarinic receptors
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
WO2008021375A3 (en) Modulators of muscarinic receptors
CL2007003580A1 (es) Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
WO2007100664A3 (en) Modulators of muscarinic receptors
MA32537B1 (fr) Dérivés de pyrazolo [5,1-b] oxazole en tant qu'antagonistes de crf1
IL209629A0 (en) Pyrrolidin - 3 - ylmethyl - amine as orexin antagonists